Christina Bæksted1, Aase Nissen2, Helle Pappot3, Pernille Envold Bidstrup4, Sandra A Mitchell5, Ethan Basch6, Susanne Oksbjerg Dalton4, Christoffer Johansen7. 1. Unit for Documentation & Quality, Danish Cancer Society, Copenhagen, Denmark; Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen, Denmark. Electronic address: baeksted@cancer.dk. 2. Unit for Documentation & Quality, Danish Cancer Society, Copenhagen, Denmark. 3. Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen, Denmark. 4. Unit of Survivorship, Danish Cancer Society, Copenhagen, Denmark. 5. Outcomes Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, USA. 6. Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA. 7. Unit of Survivorship, Danish Cancer Society, Copenhagen, Denmark; Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen, Denmark.
Abstract
CONTEXT: The Common Terminology Criteria for Adverse Events (CTCAE) is the basis for standardized clinician-based grading and reporting of adverse events in cancer clinical trials. The U.S. National Cancer Institute has developed the Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE) to incorporate patient self-reporting of symptomatic adverse events. OBJECTIVES: The aim of the study was to translate and linguistically validate a Danish language version of PRO-CTCAE. METHODS: The U.S. English language PRO-CTCAE was translated into Danish using forward and backward procedures with reconciliation. The linguistic validity of the PRO-CTCAE Danish was examined in two successive rounds of semistructured cognitive interviews in a sample of 56 patients equally distributed by gender and cancer type (prostate, head and neck, lung, breast, gynecological, gastrointestinal, and hematological cancer), and who were currently undergoing cancer treatment. RESULTS: In the first round of linguistic validation (n = 42), the phrasing of five symptomatic toxicities was adjusted, and the refined phrasing was retested in a second round of interviews (n = 14). Agreement about phrasing that was both culturally acceptable and semantically comprehensible was achieved in the second round. Statements from participants describing the meaning of the PRO-CTCAE symptomatic toxicities support conceptual equivalence to the U.S. English language version. CONCLUSION: Availability of the NCI PRO-CTCAE in languages beyond English will support international congruence in self-reporting of side effects of cancer treatment. A rigorous methodology was used to develop the Danish language version of PRO-CTCAE. Results provide preliminary support for the use of PRO-CTCAE in cancer clinical trials that include Danish speakers.
CONTEXT: The Common Terminology Criteria for Adverse Events (CTCAE) is the basis for standardized clinician-based grading and reporting of adverse events in cancer clinical trials. The U.S. National Cancer Institute has developed the Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE) to incorporate patient self-reporting of symptomatic adverse events. OBJECTIVES: The aim of the study was to translate and linguistically validate a Danish language version of PRO-CTCAE. METHODS: The U.S. English language PRO-CTCAE was translated into Danish using forward and backward procedures with reconciliation. The linguistic validity of the PRO-CTCAE Danish was examined in two successive rounds of semistructured cognitive interviews in a sample of 56 patients equally distributed by gender and cancer type (prostate, head and neck, lung, breast, gynecological, gastrointestinal, and hematological cancer), and who were currently undergoing cancer treatment. RESULTS: In the first round of linguistic validation (n = 42), the phrasing of five symptomatic toxicities was adjusted, and the refined phrasing was retested in a second round of interviews (n = 14). Agreement about phrasing that was both culturally acceptable and semantically comprehensible was achieved in the second round. Statements from participants describing the meaning of the PRO-CTCAE symptomatic toxicities support conceptual equivalence to the U.S. English language version. CONCLUSION: Availability of the NCI PRO-CTCAE in languages beyond English will support international congruence in self-reporting of side effects of cancer treatment. A rigorous methodology was used to develop the Danish language version of PRO-CTCAE. Results provide preliminary support for the use of PRO-CTCAE in cancer clinical trials that include Danish speakers.
Authors: Sebastian W Nielsen; Simone Dyring Hasselsteen; Helena Sylow Heilmann Dominiak; Dejan Labudovic; Lars Reiter; Susanne Oksbjerg Dalton; Jørn Herrstedt Journal: Support Care Cancer Date: 2022-08-06 Impact factor: 3.359
Authors: Lærke K Tolstrup; Helle Pappot; Graziella Zangger; Lars Bastholt; Ann-Dorthe Zwisler; Karin B Dieperink Journal: Health Qual Life Outcomes Date: 2018-04-27 Impact factor: 3.186
Authors: Mark A Samaan; Polychronis Pavlidis; Sophie Papa; Nick Powell; Peter M Irving Journal: Nat Rev Gastroenterol Hepatol Date: 2018-03-07 Impact factor: 46.802
Authors: Gry Assam Taarnhøj; Henriette Lindberg; Line Hammer Dohn; Lise Høj Omland; Niels Henrik Hjøllund; Christoffer Johansen; Helle Pappot Journal: Health Qual Life Outcomes Date: 2020-07-11 Impact factor: 3.186